Chronic Kidney Disease

Criteria for CKD (either of the following present for > 3 months):

1. ACR ≥ 3 mg/mmol and/or
2. Decreased eGFR < 60 ml/min/1.73m2

Kidney Failure Risk Equation (KFRE)

Treatment:

Manage Hypertension: Target BP < 120/90; Target BP < 130/80 if diabetic; use an ACEI or ARB as first-line
therapy for HTN

Manage Hyperlipidemia and Diabetes:

Lipid management: use statin if
› Age ≥ 50, or
› Age ≥ 18 with known coronary
artery disease, prior stroke,
or 10-year Framingham
risk >10%

Treat with SGLT2 inhibitors if type 2 diabetes and eGFR over 30

For adult patients with chronic kidney disease, FORXIGA (dapagliflozin) is now indicated to reduce the risk of sustained eGFR decline, end‑stage kidney disease, and cardiovascular and renal death. FORXIGA (dapagliflozin) is also indicated as an adjunct to diet, exercise, and standard of care therapy to reduce the risk of hospitalization for heart failure in adults with T2D mellitus and CV risk factors or established CV disease